Journal club #8 will be lead by PhD candidate Tharcila Chaves from the University of Groningen. She will discuss her work “Ketamine’s afterglow in treating depression and chronic pain” (abstract below).
The event is free for members, a donation is suggested from non-members. If you enjoyed our events and online content, please consider supporting APRA by becoming a member.
“Ketamine’s afterglow in treating depression and chronic pain”
Abstract: Ketamine has been showing beneficial results in treating cases of depression and chronic pain that are unresponsive to the available therapies. It is considered the biggest breakthrough in the treatment of depression in 50 years. Its use as an anaesthetic in humans (including children) for decades has demonstrated that it is a safe drug with manageable side effects. The use of ketamine as an antidepressant and analgesic is still not officially approved, but its popularity for treating these conditions is increasing, via its off-label use (i.e. legal use of a drug for different purposes than it is authorised). Nonetheless, ketamine can be addictive and its recreational use is widespread. In this scenario, the ketamine clinics are emerging, mainly in the United States, as a safe place to receive off-label ketamine infusions. The aim of this talk is to discuss the current status of ketamine as a tool to treat some mental disorders and different types of chronic pain.
Tharcila Chaves is a pharmacist, currently performing her PhD research at the University of Groningen, about the use of ketamine in treating depression and chronic pain. She has a master’s degree in medicine and sociology of drug abuse, during which she conducted a qualitative study about cravings in crack cocaine users in the city of Sao Paulo.